4.6 Review

Heart failure and kidney dysfunction: epidemiology, mechanisms and management

Journal

NATURE REVIEWS NEPHROLOGY
Volume 12, Issue 10, Pages 610-623

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrneph.2016.113

Keywords

-

Funding

  1. Fresenius Kabi
  2. GSK
  3. MSD
  4. Lilly
  5. Baxter
  6. Astellas
  7. AstraZeneca
  8. Bayer AG/Schering AG
  9. Eli Lilly
  10. Anagnostics Bionanalysis GmbH/Cube DX GesmbH
  11. Nestle
  12. Novartis
  13. Servier
  14. Cardiorentis
  15. Medtronic
  16. Vifor

Ask authors/readers for more resources

Heart failure (HF) is a major health-care problem and the prognosis of affected patients is poor. HF often coexists with a number of comorbidities of which declining renal function is of particular importance. A loss of glomerular filtration rate, as in acute kidney injury (AKI) or chronic kidney disease (CKD), independently predicts mortality and accelerates the overall progression of cardiovascular disease and HF. Importantly, cardiac and renal diseases interact in a complex bidirectional and interdependent manner in both acute and chronic settings. From a pathophysiological perspective, cardiac and renal diseases share a number of common pathways, including inflammatory and direct, cellular immune-mediated mechanisms; stress-mediated and (neuro) hormonal responses; metabolic and nutritional changes including bone and mineral disorder, altered haemodynamic and acid-base or fluid status; and the development of anaemia. In an effort to better understand the important crosstalk between the two organs, classifications such as the cardio-renal syndromes were developed. This classification might lead to a more precise understanding of the complex interdependent pathophysiology of cardiac and renal diseases. In light of exceptionally high mortality associated with coexisting HF and kidney disease, this Review describes important crosstalk between the heart and kidney, with a focus on HF and kidney disease in the acute and chronic settings. Underlying molecular and cellular pathomechanisms in HF, AKI and CKD are discussed in addition to current and future therapeutic approaches.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available